伊维菌素治疗轻中度COVID-19的疗效与安全性:随机对照试验方案结构化摘要
该文为一项在伊朗单中心开展的3期、随机、开放标签、对照试验的方案摘要,计划纳入120例轻中度COVID-19患者,评估口服伊维菌素0.2 mg/kg单次给药对比标准治疗(轻症用羟氯喹,中症用洛匹那韦/利托那韦联合干扰素β-1a)的疗效与安全性,主要终点为随机化后7天内的复合临床结局。
要点
- 伊维菌素用法为口服单次0.2 mg/kg,对照分别为羟氯喹(轻症)和洛匹那韦/利托那韦联合干扰素β-1a(中症)。
- 主要终点为随机化后7天内临床症状改善、住院需求、住院时长、ICU入住及机械通气需求等复合结局。
- 次要终点为随机化后7天内严重药物不良反应发生率。
核心结论
- 该方案旨在评估伊维菌素在轻中度COVID-19患者中的疗效与安全性,尚待试验完成后报告结果。
研究设计与样本
- 3期、单中心、随机、开放标签、对照试验,采用2臂平行组设计,按1:1比例随机分组。
- 计划纳入120例患者,其中门诊轻症60例、住院中症60例,每组各30例。
- 纳入标准包括年龄≥20岁、体重≥35kg;轻症需CT和/或胸部X线诊断轻度肺炎且无需住院,中症需PCR确诊、影像学诊断中度肺炎且住院≤48小时。
- 排除标准包括重型和危重型肺炎、AIDS、哮喘、罗阿丝虫病、严重肝肾疾病、使用抗凝药或ACE抑制剂、伊维菌素过敏史、妊娠或哺乳期。
- 采用简单随机化及随机数字表,偶数分配至治疗组、奇数分配至对照组;研究为开放标签,未设盲。
关键数值与推荐
- 干预组在伊朗卫生部标准治疗方案基础上加用口服伊维菌素(MSD公司,法国)单次0.2 mg/kg。
- 门诊对照组使用硫酸羟氯喹(Amin制药,伊朗)首日400 mg每日两次,后续7天200 mg每日两次。
- 住院对照组使用洛匹那韦/利托那韦(Heterd公司,印度)200/50 mg每日两次共7天,联合干扰素β-1a(CinnaGen,伊朗)44 mcg隔日一次共5剂。
- 主要终点为随机化后7天内的复合结局:门诊组包括临床症状改善和住院需求;住院组包括住院至出院时长、至出院前ICU入住需求和机械通气需求。
- 次要终点为随机化后7天内严重药物不良反应发生率。
临床怎么用
- 该方案为研究设计,尚不能提供伊维菌素用于COVID-19的临床实践推荐。
局限性
- 研究为单中心、开放标签设计,未设盲。
- 样本量计划为120例,规模较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We will evaluate the efficacy and safety of Ivermectin in patients with mild and moderately severe COVID-19. TRIAL DESIGN: This is a phase 3, single-center, randomized, open-label, controlled trial with a 2-arm parallel-group design (1:1 ratio). PARTICIPANTS: The Severe Acute Respiratory Syndrome Departments of the Shahid Mohammadi Hospital, Bandar Abbas, Iran, will screen for patients age ≥ 20 years and weight ≥35 kg for the following criteria: Inclusion criteria for patients with mild COVID-19 symptoms (outpatients) 1. Diagnosed mild pneumonia using computed tomography (CT) and/or chest X-ray (CX-R) imaging, not requiring hospitalization. 2. Signing informed consent. Inclusion criteria for patients with moderate COVID-19 symptoms (inpatients) 1. Confirmed infection using PCR. 2. Diagnosed moderate pneumonia using CT and/or CXR imaging, requiring hospitalization. 3. Hospitalized ≤ 48 hours. 4. Signing informed consent. Exclusion criteria 1. Severe and critical pneumonia due to COVID-19. 2. Underlying diseases, including AIDS, asthma, loiasis, and severe liver and kidney disease. 3. Use of anticoagulants (e.g., warfarin) and ACE inhibitors (e.g., captopril). 4. History of drug allergy to Ivermectin. 5. Pregnancy or breastfeeding. INTERVENTION AND COMPARATOR: Intervention groups: Outpatient and inpatient groups will receive the standard treatment regimen for mild and moderate COVID-19, based on the Iranian Ministry of Health and Medical Education's protocol, along with oral Ivermectin (MSD Company, France) at a single dose of 0.2 mg/kg. Control groups: The outpatient group will receive hydroxychloroquine sulfate (Amin Pharmaceutical Company, Iran) at a dose of 400 mg twice a day for the first day and 200 mg twice a day for seven subsequent days. The inpatient group will receive 200/50 mg Lopinavir/Ritonavir (Heterd Company, India) twice a day for the seven days, plus five doses of 44 mcg Interferon beta-1a (CinnaGen, Iran) every other day. Other supportive and routine care will be the same in both outpatient and inpatient groups. MAIN OUTCOME: The primary outcomes are composite and include the improvement of clinical symptoms and need for hospitalization for outpatient groups, and the length of hospital stay until discharge, the need for ICU admission until discharge, and the need for mechanical ventilation for inpatient groups within seven days of randomization. The secondary outcome is the incidence of serious adverse drug reactions within seven days of randomization. RANDOMIZATION: Patients in both outpatient (mild) and inpatient (moderate) groups will be randomized into the treatment and control groups based on the following method. A simple randomization method and table of random numbers will be used. If the selected number is even, the patient is allocated to the treatment group, and if it is odd, the patient is allocated to the control group in a 1:1 ratio. BLINDING (MASKING): This is an open-label study, and there is not blinding. Numbers to be randomized (sample size) A total number of 120 patients (60 outpatients and 60 patients) will be randomized into two groups (30 patients in each of the intervention groups and 30 patients in each of the control groups). TRIAL STATUS: The protocol is Version 1.0, November 17, 2020. Recruitment began November 25, 2020, and is anticipated to be completed by February 25, 2021. TRIAL REGISTRATION: This clinical trial has been registered in the Iranian Registry of Clinical Trials (IRCT). The registration number is " IRCT20200506047323N6 ". The registration date is November 17, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting the dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
引用
- Hosseini FS, Malektojari A, Ghazizadeh S, et al. The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial. Trials. 2021. PMID: 33397429. doi:10.1186/s13063-020-04988-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。